← All trials
NCT03551288
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 22, 2018
- Primary completion
- Jul 10, 2018
- Completion date
- Jul 16, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 28
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Suven Life Sciences LimitedLead sponsor
- IQVIAOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.